122 related articles for article (PubMed ID: 23036663)
1. Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index.
Magasi S; Mallick R; Kaiser K; Patel JD; Lad T; Johnson ML; Kaplan EH; Cella D
Clin Lung Cancer; 2013 May; 14(3):245-53. PubMed ID: 23036663
[TBL] [Abstract][Full Text] [Related]
2. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
3. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany.
Iyer S; Taylor-Stokes G; Roughley A
Lung Cancer; 2013 Aug; 81(2):288-93. PubMed ID: 23561304
[TBL] [Abstract][Full Text] [Related]
4. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
[TBL] [Abstract][Full Text] [Related]
5. Health state utility scores in advanced non-small cell lung cancer.
Doyle S; Lloyd A; Walker M
Lung Cancer; 2008 Dec; 62(3):374-80. PubMed ID: 18467000
[TBL] [Abstract][Full Text] [Related]
6. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
7. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
8. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.
Temel JS; Pirl WF; Lynch TJ
Clin Lung Cancer; 2006 Jan; 7(4):241-9. PubMed ID: 16512977
[TBL] [Abstract][Full Text] [Related]
10. Doxetaxel in previously treated non-small cell lung cancer patients: clinical efficacy and quality of life.
Sirisinha T; Sirilertrakul S; Jirajarus M; Ratanatharathorn V
Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):246-53. PubMed ID: 15906678
[TBL] [Abstract][Full Text] [Related]
11. A symptom cluster and sentinel symptom experienced by women with lung cancer.
Brown JK; Cooley ME; Chernecky C; Sarna L
Oncol Nurs Forum; 2011 Nov; 38(6):E425-35. PubMed ID: 22037342
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of the clinical symptoms and treatment tolerance in patients with non-small cell lung cancer (NSCLC) undergoing first-line chemotherapy and pulmonary rehabilitation].
Tokarski S; Obrebska A; Mejer A; Kowalski J
Pol Merkur Lekarski; 2014 Apr; 36(214):245-8. PubMed ID: 24868896
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer.
Fallowfield LJ; Harper P
Lung Cancer; 2005 Jun; 48(3):365-77. PubMed ID: 15893006
[TBL] [Abstract][Full Text] [Related]
14. Management of dyspnea in advanced lung cancer: recent data and emerging concepts.
Xue D; Abernethy AP
Curr Opin Support Palliat Care; 2010 Jun; 4(2):85-91. PubMed ID: 20440205
[TBL] [Abstract][Full Text] [Related]
15. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
16. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
17. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
18. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer.
Murillo JR; Koeller J
Oncologist; 2006; 11(10):1095-9. PubMed ID: 17110629
[TBL] [Abstract][Full Text] [Related]
20. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
